Advertisement

Hepatocyte Growth Factor

Physiological and Therapeutic Ligand to Attenuate Diabetic Nephropathy
  • Shinya Mizuno
  • Toshikazu Nakamura
Part of the Contemporary Diabetes book series (CDI)

Abstract

Chronic renal disease (CRD) has been considered to be irreversible (1). Renal fibrosis, a histological diagnosis of end-stage CRD, is characterized by a loss of renal parenchymal cells that are replaced by extracellular matrix (ECM) proteins, a common final pathway leading to renal dysfunction (1,2). The number of patients affected with CRD is on the increase, and dialysis market estimates indicate that more than 1 million patients worldwide have undergone maintenance dialysis. Thus, many nations are burdened with social and financial problems associated with funding health services for the dialysis of CRD patients (3). Diabetes is now the leading cause of end-stage renal disease (ESRD) in many developed countries, and diabetic nephropathy (DN) has emerged as a silent epidemic worldwide (2,3). This is certainly the case in Japan, in which diabetic kidney disease accounted for 35% of all new patients undergoing dialysis in 2003. To maintain replacement therapy, it now costs nearly $10 million per year in Japan for public financial support. Likewise, in the United States, DN accounted for 35% of all new cases of ESRD in 1997. The physical and monetary costs of diabetic kidney disease to both the patient and society are now enormous.

Keywords

Diabetic Nephropathy Hepatocyte Growth Factor Connective Tissue Growth Factor Renal Fibrosis Diabetic Kidney Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ong A, Fine LG. Loss of glomerular function and tubulointerstitial fibrosis: cause or effect? Kidney Int 1994;45:345–351.PubMedCrossRefGoogle Scholar
  2. 2.
    Akmal M. Hemodialysis in diabetic patients. Am J Kidney Dis 2001;38:S195–S199.PubMedGoogle Scholar
  3. 3.
    Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med 1996;335:1682–1683.PubMedCrossRefGoogle Scholar
  4. 4.
    Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984;122:1450–1459.PubMedCrossRefGoogle Scholar
  5. 5.
    Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440–443.PubMedCrossRefGoogle Scholar
  6. 6.
    Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci 1994;91:4357–4361.PubMedCrossRefGoogle Scholar
  7. 7.
    Igawa T, Matsumoto K, Kanda S, Saito Y, Nakamura T. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury. Am J Physiol 1993;265:F61–F69.PubMedGoogle Scholar
  8. 8.
    Miller SB, Martin DR, Kissane J, Hammerman MR. Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats. Am J Physiol 1994;266:F129–F134.PubMedGoogle Scholar
  9. 9.
    Matsumoto K, Mizuno S, Nakamura T. Hepatocyte growth factor in renal regeneration, renal disease, and potential therapeutics. Curr Opin Nephrol Hypertens 2000;9:395–402.PubMedCrossRefGoogle Scholar
  10. 10.
    Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001;59:2023–2038.PubMedGoogle Scholar
  11. 11.
    Mizuno S, Kurosawa T, Matumoto K, Mizuno-Horikawa Y, Okamoto M, Nakamura T. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 1998;101:1827–1834.PubMedGoogle Scholar
  12. 12.
    Mizuno S, Nakamura T. Suppressions of chronic glomerular injuries and TGF-β1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol 2004;286:F134–F143.Google Scholar
  13. 13.
    Ishiki Y, Ohnishi H, Muto Y, Matsumoto K, Nakamura T. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 1992;16:1227–1235.PubMedGoogle Scholar
  14. 14.
    Ohmichi H, Matsumoto K, Nakamura T. In vivo mitogenic action of HGF on lung epithelial cells: pulmotrophic role in lung regeneration. Am J Physiol 1996;270:L1031–L1039.PubMedGoogle Scholar
  15. 15.
    Takahashi M, Ota S, Terano A, et al. Hepatocyte growth factor is the most potent endogenous stimulant of rabbit gastric epithelial cell proliferation and migration in primary culture. J Clin Invest 1995;95:1994–2003.PubMedGoogle Scholar
  16. 16.
    Yoshida S, Matsumoto K, Tomioka D, et al. Recombinant hepatocyte growth factor accelerates cutaneous wound healing in diabetic mouse model. Growth Factors 2004;22:111–119.PubMedCrossRefGoogle Scholar
  17. 17.
    Funakoshi H, Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin Chim Acta 2003;327:1–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Mizuno S, Matsumoto K, Kurosawa T, Mizuno-Horikawa Y, Nakamura T. Reciprocal balance of hepatocyte growth factor and transforming growth factor-β1 in renal fibrosis in mice. Kidney Int 2001;57:937–948.CrossRefGoogle Scholar
  19. 19.
    Sakamaki Y, Matsumoto K, Mizuno S, Miyoshi S, Matsuda H, Nakamura T. Hepatocyte growth factor stimulates proliferation of respiratory epithelial cells during postpneumonectomy compenbatory lung growth in mice. Am J Respir Cell Mol Biol 2002;26:525–533.PubMedGoogle Scholar
  20. 20.
    Yoshida S, Yamaguchi Y, Itami S, et al. Neutralization of hepatocyte growth factor leads to retarded cutaneous wound healing associated with decreased neovascularization and granulation tissue formation. J Invest Dermatol 2003;120:335–343.PubMedCrossRefGoogle Scholar
  21. 21.
    Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeisson SS. Hepatocyte growth factor/c-Met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci 2004;101:4477–4482.PubMedCrossRefGoogle Scholar
  22. 22.
    Nakamura T, Nawa K, Ichihara A, Kaise N, Nishino T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 1987;224:311–316.PubMedCrossRefGoogle Scholar
  23. 23.
    Miyazawa K, Tsubouchi H, Naka D, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun 1989;163:967–973.PubMedCrossRefGoogle Scholar
  24. 24.
    Bottaro DP, Rubin JS, Faletto DL, et al. Identification of hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802–804.PubMedCrossRefGoogle Scholar
  25. 25.
    Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261–271.PubMedCrossRefGoogle Scholar
  26. 26.
    Schaeper U, Gehring NH, Fuchs KP, et al. Coupling of gab1 to c-met, grb2, and shp2 mediates biological responses. J Cell Biol 2000;149:1419–1432.PubMedCrossRefGoogle Scholar
  27. 27.
    Birchmeier C, Birchmeier W, Gherardi E, Vande-Woude GF. Met, metastasis, motility, and more. Nature Rev Mol Cell Biol 2003;4:915–925.CrossRefGoogle Scholar
  28. 28.
    Liu Y, Tolbert EM, Lin L, et al. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int 1999;55:442–453.PubMedCrossRefGoogle Scholar
  29. 29.
    Takehara T, Matsumoto K, Nakamura T. Cell density-dependent regulation of albumin synthesis and DNA synthesis in rat hepatocytes by hepatocyte growth factor. J Biochem 1992;112:330–334.PubMedGoogle Scholar
  30. 30.
    Otonkoski T, Beattie GM, Rubin JS, Lopez AD, Baird A, Hayek A. Hepatocyte growth factor/scatter factor has insulinotropic activity in human fetal pancreatic cells. Diabetes 1994;43:947–953.PubMedCrossRefGoogle Scholar
  31. 31.
    Bussolino F, Direnzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629–641.PubMedCrossRefGoogle Scholar
  32. 32.
    Nakamura Y, Morishita R, Higaki J, et al. Expression of local hepatocyte growth factor system in vascular tissue. Biochem Biophys Res Commun 1995;215:483–488.PubMedCrossRefGoogle Scholar
  33. 33.
    Aoki S, Takahashi K, Matsumoto K, Nakamura T. Activation of Met tyrosine kinase by hepatocyte growth factor is essential for internal organogenesis in Xenopus embryo. Biochem Biophys Res Commun 1997;234:8–14.PubMedCrossRefGoogle Scholar
  34. 34.
    Ohmichi H, Koshimizu U, Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 1998;125:1315–1324.PubMedGoogle Scholar
  35. 35.
    Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699–702.PubMedCrossRefGoogle Scholar
  36. 36.
    Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995;373:702–705.PubMedCrossRefGoogle Scholar
  37. 37.
    Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precurcor cells into the limb bud. Nature 1995;376:768–771.PubMedCrossRefGoogle Scholar
  38. 38.
    Takehara T, Nakamura T. Protective effect of hepatocyte growth factor on in vitro hepatitis in primary cultured hepatocytes. Biomed Res 1991;12:335–338.Google Scholar
  39. 39.
    Kosai K, Matsumoto K, Nagata S, Tsujimoto Y, Nakamura T. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 1998;244:683–690.PubMedCrossRefGoogle Scholar
  40. 40.
    Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. Myocardial protection from infarction by endogenous and exogenous hepatocyte growth factor. J Clin Invest 2000;106:1511–1519.PubMedGoogle Scholar
  41. 41.
    Miyazawa T, Matsumoto K, Ohmichi H, Yamashima T, Chigasaki H, Nakamura T. Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J Celebral Blood Flow Metabolism 1998;18:345–348.CrossRefGoogle Scholar
  42. 42.
    Yamamoto K, Morishita R, Hayashi S, et al. Contribution of Bcl-2, but not Bcl-xL and Bax, to antiapoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension 2001;37:1341–1348.PubMedGoogle Scholar
  43. 43.
    Bardelli A, Longati P, Comoglio PM, et al. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J. 1996;22:6205–6212.Google Scholar
  44. 44.
    Wang X, DeFrances MC, Dai Y, et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 2002;9:411–421.PubMedCrossRefGoogle Scholar
  45. 45.
    Oshima K, Shimamura M, Mizuno S, et al. HGF gene transfer in cerebrospinal fluid can prevent hearing impairment in rats. FASEB J 2004;18:212–214.PubMedGoogle Scholar
  46. 46.
    Nakano M, Yasunami Y, Maki T, et al. Hepatocyte growth factor is essential for amelioration of hyperglycemia in streptozotocin-induced diabetic mice receiving a marginal mass of intrahepatic islet grafts. Transplantation 2000;69:214–222.PubMedCrossRefGoogle Scholar
  47. 47.
    Warzecha Z, Dembinski A, Ceranowicz P, et al. Inhibition of cyclooxygenase-2 reduces the protective effect of hepatocyte growth factor in experimenal pancreatitis. Eur J Pharmacol 2004;486:107–119.PubMedCrossRefGoogle Scholar
  48. 48.
    Igawa T, Kanda S, Kanetake H, et al. Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells. Biochem Biophys Res Commun 1991;174:831–838.PubMedCrossRefGoogle Scholar
  49. 49.
    Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991;67:901–908.PubMedCrossRefGoogle Scholar
  50. 50.
    Ishibashi K, Sasaki S, Sakamoto H, et al. Hepatocyte growth factor is a paracrine factor for renal epithelial cells: Stimulation of DNA synthesis and Na,K-ATPase activity. Biochem Biophys Res Commun 1992;182:960–965.PubMedCrossRefGoogle Scholar
  51. 51.
    Yo Y, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apototic action of HGF on epithelial cells. Kidney Int 1998;54:1128–1138.PubMedCrossRefGoogle Scholar
  52. 52.
    Fornoni A, Li H, Foschi A, Striker GE, Striker LJ. Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis. Am J Pathol 2001;158:275–280.PubMedGoogle Scholar
  53. 53.
    Mori T, Shimizu A, Masuda Y, Fukuda Y, Yamanaka N. Hepatocyte growth factor-stimulating endothelial cell growth and accelerating glomerular capillary repair in experimental progressive glomerulonephritis. Nephron Exp Nephrol 2003;94:44–54.CrossRefGoogle Scholar
  54. 54.
    Biswas P, Roy A, Gong R, et al. Hepatocyte growth factor induces an endothelin-mediated decline in glomerular filtration rate. Am J Physiol 2005;288:F8–F15.Google Scholar
  55. 55.
    Lowenstein LM, Stern A. Serum factor in renal compensatory hyperplasia. Science 1963;142:1479.PubMedCrossRefGoogle Scholar
  56. 56.
    Nagaike M, Hirao S, Tajima H, et al. Renotropic functions of hepatocyte growth factor in renal regeneration after unilateral nephrectomy. J Biol Chem 1991;266:22,781–22,784.PubMedGoogle Scholar
  57. 57.
    Barros EJG, Santos OFP, Matsumoto K, Nakamura T, Nigam SK. Differential tubulogenic and branching morphogenetic activities of growth factors: Implications for epithelial tissue development. Proc Natl Acad Sci 1995;92:4412–4416.PubMedCrossRefGoogle Scholar
  58. 58.
    Amaike H, Matsumoto K, Oka T, Nakamura T. Human recombinant HGF prevents lethal side effects of cyclosporin A in mice. Cytokine 1996;8:387–394.PubMedCrossRefGoogle Scholar
  59. 59.
    Takada S, Takahara S, Nishimura K, et al. Effect of hepatocyte growth factor on tacrolimus-induced nephrotoxicity in spontaneously hypertensive rats. Transpl Int 1999;12:27–32.PubMedCrossRefGoogle Scholar
  60. 60.
    Nagano T, Mori-Kudo I, Kawamura T, Taiji M, Noguchi H. Pre-or post-treatment with hepatocyte growth factor prevents glycerol-induced acute renal failure. Renal Fail 2004;26:5–11.CrossRefGoogle Scholar
  61. 61.
    Mizuno S, Nakamura T. Prevention of neutrophil extravasation by HGF leads to attenuations of tubular apoptosis and renal dysfunction in mouse ischemic kidneys. Am J Pathol 2005;166:1895–1905.PubMedGoogle Scholar
  62. 62.
    Matsumoto K, Nakamura T. Hepatocyte growth factor as a renotropic factor and therapeutic potential for acute renal failure. In: M. S. Goligorosky, ed. Acute Renal Failure: Emerging New Concepts and Therapeutic Strategies. Churchill Livingstone, 1995, pp.450–474.Google Scholar
  63. 63.
    Risdon RA, Sloper JC, Wardener WH. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968;2:363–366.PubMedCrossRefGoogle Scholar
  64. 64.
    Kopp JB. Hepatocyte growth factor: Mesenchymal signal for epithelial homeostasis. Kidney Int 1998;54:1392–1393.PubMedCrossRefGoogle Scholar
  65. 65.
    Balkovetz DF, Lipschutz JH. Hepatocyte growth factor and the kidney: it is not just for the liver. Int Rev Cytol 1999;186:225–260.PubMedGoogle Scholar
  66. 66.
    Matsuda Y, Matsumoto K, Tsuchida T, Nakamura T. Hepatocyte growth factor prevents liver cirrhosis caused by dimethylnitrosamine in rats. J Biochem 1995;118:643–649.PubMedGoogle Scholar
  67. 67.
    Yaekashiwa M, Nakamura S, Ohnuma K, et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin: a morphologic study. Am J Respir Crit Care Med 1997;156:1937–1944.PubMedGoogle Scholar
  68. 68.
    Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994;331:1286–1292.PubMedCrossRefGoogle Scholar
  69. 69.
    Mizuno S, Yue BF, Okamoto M, Horikawa Y, Kurosawa T. Diffuse glomerulosclerosis without tubular injury does not manifest renal dysfunction in nephrotic mice (ICGN strain). Exp Nephrol 1997;5:498–507.PubMedGoogle Scholar
  70. 70.
    Klahr S. Obstructive nephropathy. Kidney Int 1998;54:286–300.PubMedGoogle Scholar
  71. 71.
    Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Intl 2001;59:1304–1314.CrossRefGoogle Scholar
  72. 72.
    Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002;13:96–107.PubMedGoogle Scholar
  73. 73.
    Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol 2004;287:F7–F16.CrossRefGoogle Scholar
  74. 74.
    Florquin S, Rouschop KM. Reciprocal functions of hepatocyte growth factor and transforming growth factor-β1 in the progression of renal diseases: a role for CD44? Kidney Int 2003;86:S15–S20.CrossRefGoogle Scholar
  75. 75.
    Liu Y, Raju K, Tolbert E, Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 2000;58:2028–2043.PubMedCrossRefGoogle Scholar
  76. 76.
    Inoue T, Okada H, Kobayashi T, et al. Hepatocyte growth factor counteracts transforming growth factor-β1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB J 2003;17:268–270.PubMedGoogle Scholar
  77. 77.
    Isaka Y, Yamada K, Takabatake Y, et al. Electroparation-mediated HGF gene transfection protected the kidney against graft injury. Gene Ther 2005;12:815–820.PubMedCrossRefGoogle Scholar
  78. 78.
    Azuma H, Takahara S, Matsumoto K, et al. Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol 2001;12:1280–1292.PubMedGoogle Scholar
  79. 79.
    Ziyadeh FN, Hoffman BB, Han CC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci 2000;97:8015–8020.PubMedCrossRefGoogle Scholar
  80. 80.
    Goldfar S, Ziyadeh FN. TGF-β: a crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc 2001;112:27–32.Google Scholar
  81. 81.
    Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993;92:2597–2601PubMedGoogle Scholar
  82. 82.
    Morishita R, Nakamura S, Nakamura Y, et al. Potential role of an endothelium specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 1997;46:138–142.PubMedCrossRefGoogle Scholar
  83. 83.
    Liu Y, Tolbert EM, Sun AM, Dworkin LD. In vivo and in vitro evidence for increased expression of HGF receptor in kidney of diabetic rats. Am J Physiol 1996;271:F1202–F1210.PubMedGoogle Scholar
  84. 84.
    Nakamura S, Morishita R, Moriguchi A, et al. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J Hypertensions 1998;16:2019–2026.CrossRefGoogle Scholar
  85. 85.
    Kulseng B, Borset M, Espevik T, Sundan A. Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus. Acta Diabetol 1998;35:77–80.PubMedCrossRefGoogle Scholar
  86. 86.
    Bessho K, Mizuno S, Matsumoto K, Nakamura T. Counteractive effects of HGF on PDGF-induced mesangial cell proliferation in a rat model of glomerulonephritis. Am J Physiol 2003;284:F1171–F1180.Google Scholar
  87. 87.
    Nakamura Y, Morishita R, Higaki J, et al. A vascular modulator, hepatocyte growth factor (HGF), is associated with systolic blood pressure. Hypertension 1996;28:409–413.PubMedGoogle Scholar
  88. 88.
    Matsumoto K, Tajima H, Okazaki H, Nakamura T. Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-β1 and glucocorticoids. J Biol Chem 1992;267:24,917–24,920.PubMedGoogle Scholar
  89. 89.
    Yo Y, Morishita R, Yamamoto K, et al. Actions of hepatocyte growth factor as a local modulator in the kidney: potential role in pathogenesis of renal disease. Kidney Int 1998;53:50–58.PubMedCrossRefGoogle Scholar
  90. 90.
    Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 1999;56:1627–1637.PubMedCrossRefGoogle Scholar
  91. 91.
    Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495–2508.PubMedGoogle Scholar
  92. 92.
    Shimizu H, Maruyama S, Yuzawa Y, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injuries induced by protein-overload proteinuria. J Am Soc Nephrol 2003;14:1496–1505.PubMedCrossRefGoogle Scholar
  93. 93.
    Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, Dworkin LD. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol 2004;15:2868–2881.PubMedCrossRefGoogle Scholar
  94. 94.
    Matsumoto K, Morishita R, Tomita N, et al. Improvement of endothelial dysfunction by angiotensin II blockade accompanied by induction of vascular hepatocyte growth factor system in diabetic spontaneously hypertensive rats. Heart Vessels 2003;18:18–25.PubMedCrossRefGoogle Scholar
  95. 95.
    Yang R, Bunting S, Ko A, Schwall R, Jin H. Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharm 1997;30:294–301.CrossRefGoogle Scholar
  96. 96.
    Kriz W, Lemley KV. The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 1999;8:489–497.PubMedCrossRefGoogle Scholar
  97. 97.
    Wald H, Scherzer P, Rasch R, Popovtzer MM. Renal tubular Na+-K+-ATPase in diabetes mellitus: relationship to metabolic abnormality. Am J Physiol 1993;265:E96–E101.PubMedGoogle Scholar
  98. 98.
    Nakamura T, Tomita Y, Hirai R, Yamaoka K, Kaji K, Ichihara A. Inhibitory effect of transforming growth factor-β on DNA synthesis of adult rat hepatocytes in primary culture. Biochem Biophys Res Commun 1985;133:1042–1050.PubMedCrossRefGoogle Scholar
  99. 99.
    Taipale J, Keski OJ. Hepatocyte growth factor releases epithelial andendothelial cells from growth arrest induced by transforming growth factor-β1. J Biol Chem 1996;271:4342–4348.PubMedCrossRefGoogle Scholar
  100. 100.
    Santos OFP, Nigam SK. HGF-induced tubulogenesis and branching of epithelial cells is modulated by extracellular matrix and TGF-β. Dev Biol 1993;160:293–302.PubMedCrossRefGoogle Scholar
  101. 101.
    Dai C, Liu Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF-β1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol 2004;15:1402–1412.PubMedCrossRefGoogle Scholar
  102. 102.
    Pepper MS, Matsumoto K, Nakamura T, Orci L, Montesano R. Hepatocyte growth factor induces urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in MDCK epithelial cells. J Biol Chem 1992;267:20,493–20,496.PubMedGoogle Scholar
  103. 103.
    Mizuno S, Matsumoto K, Li MY, Nakamura T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005;19:580–582.PubMedGoogle Scholar
  104. 104.
    Dworkin LD, Gong R, Tolbert E, et al. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int 2004;65:409–419.PubMedCrossRefGoogle Scholar
  105. 105.
    Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226–230.PubMedCrossRefGoogle Scholar
  106. 106.
    Matsumoto K, Morishita R, Moriguchi A, et al. Prevention of renal damage by Angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension. 1999;34,279–34,284.Google Scholar
  107. 107.
    Yang J, Dai C, Liu Y. Hepatocyte growth factor gene therapy and angiotensin-II blockade synergiastically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002;13:2464–2477.PubMedCrossRefGoogle Scholar
  108. 108.
    Nakamura T, Matsumoto K, Mizuno S, Sawa Y, Matsuda H, Nakamura T. Hepatocyte growth factor prevents tissue fibrosis, remodeling and dysfunction in cardiomyopathic hamster hearts. Am J Physiol 2005;288:H2131–H2139.Google Scholar
  109. 109.
    Wu MH, Yokozeki H, Takagawa S, et al. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther 2004;11:170–180.PubMedCrossRefGoogle Scholar
  110. 110.
    Nahas AMEL, Muchaneta-Kubara H, Essawy M, Soylemezoglu O. Renal fibrosis: Insights into pathogenesis and treatment. Int J Biochem Cell Biol 1997;29:55–56.PubMedCrossRefGoogle Scholar
  111. 111.
    Gressner AM. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol 1995;22:28–36.PubMedCrossRefGoogle Scholar
  112. 112.
    Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002;122(6):286S–289S.PubMedCrossRefGoogle Scholar
  113. 113.
    Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J. Mesangial cell apoptosis: the major mechanism for resolution of glomerular cellularity in experimental mesangial proliferative nephritis. J Clin Invest 1994;94:2105–2116.PubMedGoogle Scholar
  114. 114.
    Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis: Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538–549.PubMedCrossRefGoogle Scholar
  115. 115.
    Kim HW, Matsumoto K, Bessho K, Nakamura T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol 2005;166:1017–1028.PubMedGoogle Scholar
  116. 116.
    Almeida EA, Ilic D, Han Q, et al. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J Cell Biol 2000;149:741–754.PubMedCrossRefGoogle Scholar
  117. 117.
    Johnson RJ, Raines EW, Floege J, et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulo-nephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992;175:1413–1416.PubMedCrossRefGoogle Scholar
  118. 118.
    Ono M, Sawa Y, Mizuno S, et al. Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats. Circulation 2004;110:2896–2902.PubMedCrossRefGoogle Scholar
  119. 119.
    Yang J, Dai C, Liu Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts smad signal transduction. Am J Pathol 2003;163:621–632.PubMedGoogle Scholar
  120. 120.
    Cruzado JM, Lloberas N, Torras J, et al. Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes 2004;53:1119–1127.PubMedCrossRefGoogle Scholar
  121. 121.
    Kobayashi E, Sasamura H, Mifune M, et al. Hepatocyte growth factor regulates proteoglycan synthesis in interstitial fibroblasts. Kidney Int 2003;64:1179–1188.PubMedCrossRefGoogle Scholar
  122. 122.
    Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004;44:203–209.PubMedCrossRefGoogle Scholar
  123. 123.
    Tajima H, Higuchi O, Mizuno K, Nakamura T. Tissue distribution of hepatocyte growth factor receptor and its exclusive down-regulation in a regenerating organ after injury. J Biochem 1992;111:401–406.PubMedGoogle Scholar
  124. 124.
    Hashigasako A, Machide M, Nakamura T, Matsumoto K, Nakamura T. Bi-directional regulation of c-Met Ser 985 phosphorylation via PKC and protein phosphatase 2A involves c-Met activation and cellular responsiveness to HGF. J Biol Chem 2004;279:26,445–26,452.PubMedCrossRefGoogle Scholar
  125. 125.
    Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol 2004;15:2637–2647.PubMedCrossRefGoogle Scholar
  126. 126.
    Dai C, Li Y, Yang J, Liu Y. Hepatocyte growth factor preserves beta cell mass and mitigates hyperglycemia in streptozotocin-induced diabetic mice. J Biol Chem 2003;278:27,080–27,087.PubMedCrossRefGoogle Scholar
  127. 127.
    Kato N, Nemoto K, Nakanishi K, et al. Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes 2005;54:846–854.PubMedCrossRefGoogle Scholar
  128. 128.
    Okada H, Watanabe Y, Inoue T, et al. Transgene-derived hepatocyte growth factor attenuates reactive renal fibrosis in aristolochic acid nephrotoxicity. Nephrol Dial Transplant 2003;18:2515–2523.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Shinya Mizuno
    • 1
  • Toshikazu Nakamura
    • 1
  1. 1.Division of Molecular Regenerative Medicine, Department of Molecular Regenerative MedicineOsaka University Graduate School of MedicineSuita OsakaJapan

Personalised recommendations